Video

Recent Updates in PARP Inhibitor Indications for Ovarian Cancer

Author(s):

Bradley J. Monk, MD, FACS, FACOGRobert L. Coleman, MD, FACOG, FACS

Dr Robert Coleman reviews data from the ARIEL-4 trial on rucaparib in recurrent ovarian cancer, sparking a discussion on PARP inhibitor use.

Related Videos
Video 14 - "Key Takeaways in HER2-Mutated NSCLC"
Video 13 - "Treatment Considerations in HER2-Mutated NSCLC"
A panel of 5 experts on lung cancer
A panel of 5 experts on lung cancer
Video 18 - "Reflecting on Differentiated Thyroid Cancer: Final Insights"
Video 17 - "Phase 2 ATLEP Trial Results"
Emil Lou, MD, PhD, FACP
A panel of 5 experts on lung cancer
A panel of 5 experts on lung cancer
Amma Asare, MD, PhD
Related Content
OncLive On Air
May 30th 2024

Revisit Every OncLive On Air Episode From May 2024

Vadim Gushchin, MD; Teresa Diaz-Montes, MD, MPH, FACOG
April 20th 2023

Gushchin and Diaz-Montes Describe QOL Outcomes After Cytoreduction and HIPEC in Ovarian Cancer

Rowan T. Chlebowski, MD, PhD
May 23rd 2024

Long-Term Findings Clarify Role of Estrogen Therapy on Ovarian/Endometrial Cancer Incidence

Monk Recaps Benefit of Rucaparib Maintenance Therapy in Advanced Ovarian Cancer
July 18th 2022

Monk Recaps Benefit of Rucaparib Maintenance Therapy in Advanced Ovarian Cancer

Timothy Yap, MBBS, PhD, FRCP
May 21st 2024

First-in-Class PARP1 Selective Inhibitor Saruparib Shines in Phase 1 Trial of Advanced Solid Tumors

Emil Lou, MD, PhD, FACP, of the University of Minnesota Medical School
May 17th 2024

Prognostic Study Correlates TSP and Clinical Outcomes in High-Grade Serous Ovarian Cancer